BRITISH CANNABIS™ Confirmed as UK’s Preeminent Legal CBD Product Maker


Ryan Allway

April 1st, 2022

News, Top News


BRITISH CANNABIS, registered as CBD Health Foods Ltd, celebrated the monumental break-through of 310 of its products successfully passing onto the crucial next stage of the UK Novel Foods process for CBD food supplements.

 

On Thursday 31st March 2022, the UK’s Food Standards Agency updated the public list of CBD food products linked to novel food applications, with 3,536 individual products either carrying a ‘Validated’ or ‘Awaiting Evidence’ status.

 

Possessing 310 unique products, across 15 thorough applications (20% of all applications through to the next stage), gives BRITISH CANNABIS™ the highest number of products permitted for general sale of any brand or manufacturer.

 

This resulting 9% share of the UK market by choice of products includes 75 of the company’s own-brand portfolio, from the CBD by BRITISH CANNABIS™ (FKA Canabidol™), Access CBD™ and CBD Health™ ranges. Also progressing on towards the ‘validation stage’ are 235 individual products across several leading brands ‘Powered by BRITISH CANNABIS™’ under the company’s white label manufacturing services.

 

The products prominent in the FSA public list made by BRITISH CANNABIS™ include sublingual CBD oils, CBD capsules and edible food products such as CBD gummies and Gel-Tabs™.

 

Following on from yesterday’s announcements, the thousands of other products that are not present on the FSA public list are recommended to be removed from sale in retailers across the UK, with Trading Standards set to roll out plans for enforcement in the coming weeks.

 

The news comes at a critical moment for the CBD products industry as brands and manufacturers sold on the UK market, on or before February 2020, were invited to apply for pre-market authorisation, with a deadline of 31st March 2021. In the interim, the FSA has been considering the evidence presented by over 800 applications, covering an estimated 10,000 products attempting to stay on the market.

 

Making this achievement of particular note is the fact that BRITISH CANNABIS™ products are among the few remaining on the market to use ‘100% cannabis”, naturally derived formulas in their CBD oils, thus they contain the hundreds of clinically proven plant phytochemicals found in cannabis, whilst also being 0% THC. Their food supplements are also free from other restricted cannabinoids.

 

BRITISH CANNABIS™ CEO, Thomas Whettem, reacted shortly after hearing the big news: This is a monumental moment for our company and a recognition of 3 years of work and investment from myself and our dedicated project team. Our aim from the start in 2015 has been to act as an authority when it comes to CBD products that people can trust. Now, having cornered the market with nearly 1-in-10 of the CBD products remaining legal to sell in the UK, I am galvanised that we are on our way to achieving this goal.

 

We had 15 individual Novel Foods dossier submissions to the FSA, spanning thousands of pages and many hours of providing evidence. This gave us a substantial 20% of all of the RP numbers appearing on this public list today. The evidence gathered included our thorough testing, product safety and purity, and our passion for compliant products that do and contain what we say they do. It’s our vision that retailers and consumers alike will be able to continue to place their trust in BRITISH CANNABIS™ for many years to come”.

 

BRITISH CANNABIS™ Managing Director, David Ralson, added: I can hardly put into words how excited and proud this announcement makes me, both for my team and for all of the customers that support our products. To be confirmed at this time as the most predominate manufacturer in the UK for the number of products on the FSA public list is gratifying for all of the dedication we have put into doing things the best way possible and in order to make our products sustainable for the future.

 

Our partners at the ACI (Association for The Cannabinoid Industry) have been supporting us in progressive communication along the way with both the FSA and Trading Standards. As soon as the consortium toxicology study that we have partaken in with the ACI and its members is ready for release, we look forward to our products currently listed as ‘Awaiting Evidence’ on the public list to move on to ‘Validated’ status, and then to full approval in the next year or two.

 

I would encourage all of our customers and consumers, existing and future, to check the FSA public list carefully; is your CBD supplement on the list? If not, why? Our Primary Partnership with Berkshire & Buckinghamshire Trading Standards sees us ready to advise retailers who have questions about this process and what compliant CBD products they should be stocking. We are delighted to be able to offer them a greater choice of compliant cannabis food products moving forward than any other manufacturer.”

 

 

BRITISH CANNABIS™ can be reached on +44 (0) 203 965 2420 or via email at [email protected]

 

 

BRITISH CANNABIS™ – A UK CBD Industry Original

 

BRITISH CANNABIS™ is the largest producer, manufacturer, and distributor of legal cannabis-derived products in the UK. They own and operate a unique extraction and purification facility in England and provide analytical testing, bulk extracts and white label products to the UK market leading brands.

 

With over a thousand CBD food supplement products, included across no less than 15 thorough applications to the Food Standards Agency, the makers of CBD By British Cannabis™, ACCESS CBD™ and many successful white label brands are set to bring cannabis-based wellness products to the people for years to come.

 

Press release distributed by Pressat on behalf of British Cannabis, on Friday 1 April, 2022. For more information subscribe and follow https://pressat.co.uk/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading